Categories AlphaGraphs, Earnings, Other Industries

Alexion Pharmaceutical sales spike by 14% in Q2

Alexion Pharmaceutical Thursday reported 14% increase in revenue for the second quarter, riding on a 16% volume hike. The company, however, swung to a loss of $2.05 per share from a profit of $0.73 per share a year ago as operating expenses doubled due to certain charges related to the acquisition of Wilson Therapeutics. Excluding these charges, earnings improved 33% to $2.07 per share.

Revenue for the quarter stood at $1.05 billion. The results surpassed projections set by analysts.

“We have advanced our ALXN1210 programs with the goal of improving the standard of care for patients and have filed regulatory submissions for PNH in the U.S. and EU, and pending regulatory approval, plan to launch next year.” CEO Ludwig Hantson said in a statement.

Alexion Pharma product sales trend

During the quarter, sales of the company’s flagship Soliris drug, used in the treatment of rare blood-related diseases, increased 10% to $898.2 million. Volume improved 11% year-over-year.

Elated by the strong performance in the second quarter, the Connecticut-based company raised its revenue and income expectations for the full year. The company now expects non-GAAP earnings in the range of $7.00 to $7.15 per share on a total revenue of $3.98 billion to $4.01 billion for FY18.

Earlier, the company had projected non-GAAP earnings of $6.75 to $6.90 per share on revenue of $3.925 billion to $3.985 billion. Alexion stock gained over 2% in pre-market trading on Thursday.

Related: Alexion Q1 results (Click to enlarge image)

Alexion earnings infographic
Alexion Pharmaceuticals Q1 2018 Earnings Infographic

Most Popular

MU Earnings: Micron’s Q4 profit declines but beats estimates

Micron Technology Inc. (NASDAQ: MU) Thursday said its fourth-quarter profit declined from last year, hurt by a sharp fall in revenues. Earnings, however, beat the market’s projection. On an adjusted

What are Philip Morris’ (PM) anticipations for the near term?

Shares of Philip Morris International Inc. (NYSE: PM) were down 1% on Thursday. The stock has dropped over 9% year-to-date. Although the tobacco industry has felt the pinch of inflation,

Key highlights from CarMax (KMX) Q2 2023 earnings results

CarMax, Inc. (NYSE:KMX) reported second quarter 2023 earnings results today. Net revenues rose 2% year-over-year to $8.1 billion. Net earnings were $125.9 million, or $0.79 per share, compared to $285.2 million,

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top